This appears to be a good entry point for a nice run. Strong buy at stoxline website this morning with the $6.25 target price in six months.
My realistic run-up target to Phase 3 data in ESTABLISH-2 is $7-7.50 with a pop into the $8-9 range on positive data.
Sentiment: Strong Buy
Yes, this is reasonable for a new MRSA killer that is more efficient (only 6 days of treatment) than Zyvox and kills bugs that may be resistant to Zyvox or other treatments. Easy money for patience, that is all.